#United States #New York #Class Action #Pomerantz LLP #Acadia Pharmaceuticals

Investigating Claims Against ACADIA Pharmaceuticals

Overview

On October 28, 2025, the Pomerantz Law Firm launched an investigation into potential securities fraud involving ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). This investigation pertains to claims made by investors concerning the company's business practices and the integrity of its financial disclosures. Investors concerned about their rights or the validity of the company's actions are encouraged to reach out to the law firm for assistance.

Background of ACADIA Pharmaceuticals

ACADIA Pharmaceuticals, a biopharmaceutical company specializing in developing innovative treatments for central nervous system disorders, has piqued the interest of investors primarily due to its unique focus on indications such as Prader-Willi syndrome. However, recent developments have raised serious concerns regarding their operational transparency and product efficacy.

Recent Press Release and Findings

The trigger for the investigation was a press release issued by ACADIA on September 24, 2025. In this announcement, the company disclosed the results of the Phase 3 COMPASS trial, which evaluated the efficacy of their drug, intranasal carbetocin (ACP-101), for treating hyperphagia in patients with Prader-Willi syndrome. Unfortunately for investors, this trial resulted in disappointing findings. The drug failed to demonstrate a meaningful improvement over a placebo on the study's primary endpoint, which focused on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). More distressingly, it did not meet any of the secondary endpoints either.

Following the disclosure of these results, ACADIA’s stock plummeted, closing at $21.26 on September 24, marking a staggering drop of 9.92% or a loss of $2.34 per share. This sudden loss has led to speculation about the awareness and handling of the trial results by the company's leadership, prompting Pomerantz's intervention.

Legal Implications

The Pomerantz Law Firm, known for its expertise in corporate litigation, particularly related to securities and antitrust matters, is now scrutinizing whether executives at ACADIA Pharmaceuticals failed to uphold their fiduciary duties and if they engaged in practices that could be considered securities fraud. This thorough investigation reflects the firm’s commitment to safeguarding investor rights and holding corporations accountable for their actions.

As part of its classic approach, the firm urges impacted investors to join the class action lawsuit aimed at recovering damages tied to the stock's decline after the alarming press release.

Contact Information

For those who may have claims or wish to learn more about their rights, Pomerantz advises contacting Danielle Peyton at [email protected] or via phone at 646-581-9980, extension 7980. They aim to gather testimonies and strengthen the investigation's foundation.

Importance of Investment Vigilance

This case underlines the necessity of investors being vigilant and informed about the businesses they invest in. With the potential for fraud and misrepresentation, investors need to perform due diligence and remain aware of any discrepancies in a company’s reporting of financial data and clinical trial outcomes.

With the landscape of the pharmaceutical industry constantly evolving, staying informed about not only the products but also the management practices of biopharmaceutical companies can be crucial for safeguarding one’s investments. The Pomerantz investigation aims to shine a light on the unfolding situation and to advocate for fairness and transparency in corporate dealings.